Form D Explorer
Crosslink Therapeutics Inc. · CIK 2067583

Report a data issueCitable research briefCompare issuerPrivate research collection

Crosslink Therapeutics Inc.

CIK 2067583 · Corporation · Inc. DELAWARE · BOSTON, Massachusetts · Pharmaceuticals

These Form D notices describe private placements reported to the SEC. Read Form D/A amendments alongside the original disclosures.

Filings
2
Original notices
2
Amendments
0
Activity
May 15, 2025
through Oct 20, 2026

Figures are issuer-reported and describe stored filings. Data coverage and methodology.

Differences between reported disclosures

Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.

Unavailable values are shown as a dash; reported zero remains zero.
FieldMay 15, 2025 · DOct 20, 2026 · DLater minus earlier
Reported offering amount$8,000,000$5,500,000$-2,500,000
Reported amount sold$4,250,000$5,500,000$1,250,000
Reported investor count—8—
Reported minimum investment$0$0$0

Earlier SEC source: 0002067583-25-000002 · Later SEC source: 0002067583-26-000002

Choose filings to compare · Research this issuer step by step

Latest available filing snapshot: how to read these fields

Form D · Oct 20, 2026

Reported offering amount
$5,500,000
Reported exemptions
Rule 506(b)
Reported amount sold
$5,500,000

This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.

Filings by year

Submission counts, including amendments; not dollars raised or distinct funding rounds.

Related person name and locality match

Matches in stored disclosures are research leads. They do not establish common ownership or confirm identity.

Form D filings (2)